Upgrade to SI Premium - Free Trial

TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO)

June 24, 2024 11:41 AM
TD Cowen analyst Tyler Van Buren reiterated a Buy rating on BridgeBio Pharma (NASDAQ: BBIO) following data from Alnylam Pharma ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles